Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
The Motley Fool May 2, 2005 Brian Gorman	Cardinal Health Perks Up The drug distribution company is working through its problems, which should make for a brighter fiscal 2006. Investors, take note.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool June 28, 2005 Brian Gorman	Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
The Motley Fool November 8, 2011 Brandon Glenn	Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
The Motley Fool November 2, 2006 Rich Duprey	Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.
The Motley Fool June 27, 2011 Brandon Glenn	Cardinal Health Products Won't Be in Cleveland Medical Mart (or Any Other) Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health has had an apparent change of opinion.
The Motley Fool January 26, 2007 Billy Fisher	A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool March 24, 2005 Brian Gorman	Eli Lilly Turns to Japan The company's move to focus more resources on Japan makes good sense.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool July 2, 2010 Brian Orelli	Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get?
The Motley Fool November 7, 2007 Billy Fisher	Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool May 18, 2005 Brian Gorman	Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool May 23, 2006 Rich Duprey	Eisai Has a Yen for Profits With new formulations for its current drugs planned for release, expansion of its blockbuster drug Aricept possible, and with a few new drugs in the pipeline, the Japanese pharmaceutical is poised to continue churning out record revenues and earnings that investors won't soon forget.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
BusinessWeek April 15, 2010 Kanoko Matsuyama	Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
Chemistry World May 31, 2013 Phillip Broadwith	Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases.
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool March 7, 2007 Rich Duprey	Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool April 19, 2011 Brian Orelli	See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff?
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
ifeminists December 28, 2005 Tony Zizza	If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs.
The Motley Fool March 23, 2011 Jordan DiPietro	Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock?
The Motley Fool December 11, 2007 Brian Lawler	The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool November 1, 2005 Rich Duprey	Eisai's Good Medicine The Japanese pharmaceutical reports record sales and earnings on the strength of its Alzheimer's treatment. Sales and profit growth have caused Eisai's share price to surge by about 33% since the beginning of the year.
The Motley Fool May 15, 2007 Rich Duprey	Eisai Doles Out Tough Medicine The Japanese pharmaceutical company wins a patent infringement decision regarding its heartburn treatment. Investors, take note.
The Motley Fool September 8, 2006 Brian Lawler	Ligand's Drug Sale For the pharmaceutical's marketed drugs, everything must go. Investors, take note.
The Motley Fool March 31, 2008 Rich Duprey	Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment.
BusinessWeek February 25, 2010 Weintraub & Tirrell	Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed.
The Motley Fool May 2, 2008 Steven Renaldi	Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool March 17, 2006 Rich Duprey	Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note.